Neurocrine Biosciences Inc vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Neurocrine Biosciences Inc trades at $143.3 (market cap $14.36B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.11 (market cap $14.70B). The key difference: Neurocrine Biosciences Inc and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. are close in size by market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.47% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | ZTO | |
|---|---|---|
Market Cap | $14.36B | $14.70B |
Volume | 1,237,180 | 1,484,646 |
Sector | Health | Industrials |
52-Week High | $185.50 | $25.88 |
52-Week Low | $123.10 | $18.50 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $14.37B | $13.32B |
Dividend Yield | — | 3.47% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
No Aura AI signal available yet.
Trailing returns across standard periods
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →